Development and validation of blood-based biomarkers for improved heart failure management
Chronic heart failure (HF) is an epidemic affecting approximately 1.5-2% of Canada’s population (12% in patients over 80yrs) and the current one-year mortality rate after HF diagnosis remains disturbingly high at 25-40%. Even with treatment, many HF patients require hospitalizations during the course of their disease; in Canada HF is responsible for $3 billion in hospital costs annually. HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) are two phenotypes of heart failure with different underlying etiologies but similar clinical presentation, and mortality rates. The purpose of this research is to identify predictive blood-based biomarker signatures that can discriminate different heart failure phenotypes. In addition, prognostic biomarker panels of heart failure outcomes will be identified in subjects with advanced heart failure. Method development of integrative algorithms for big data will be utilized on heart failure datasets.